title: Comparison of acute hemodynamic effects of inhaled nitric oxide and inhaled epoprostenol in patients with pulmonary hypertension.
abstract: Inhaled nitric oxide (iNO) is used for acute vasoreactivity testing in pulmonary arterial hypertension (PAH) patients. Inhaled epoprostenol (iPGI2) has pulmonary selectivity and is less costly. We sought to compare acute hemodynamic effects of iNO (20 ppm) and iPGI2 (50 ng/kg/min) and determine whether their combination has additive effects. We conducted a prospective, single center, randomized, cross-over study in 12 patients with PAH and seven with heart failure with preserved ejection fraction (HFpEF). In PAH patients, iNO lowered mean pulmonary artery pressure (mPAP) by 9 ± 12% and pulmonary vascular resistance (PVR) by 14 ± 32% (mean ± SD). iPGI2 decreased mPAP by 10 ± 12% and PVR by 12 ± 36%. Responses to iNO and iPGI2 in mPAP and PVR were directly correlated (r(2) = 0.68, 0.70, respectively, P < 0.001). In HFpEF patients, mPAP dropped by 4 ± 7% with each agent, and PVR dropped by 33 ± 23% with iNO, and by 25 ± 29% with iPGI2 (P = NS). Pulmonary artery wedge pressure (PAWP) increased significantly with iPGI2 versus baseline (20 ± 3 vs. 17 ± 2 mmHg, P = 0.02) and trended toward an increase with iNO and the combination (20 ± 2, 19 ± 4 mmHg, respectively). There were no additive effects in either group. In PAH patients, the vasodilator effects of iNO and iPGI2 correlated at the doses used, making iPGI2 a possible alternative for testing acute vasoreactivity, but their combination lacks additive effect. Exposure of HFpEF patients to inhaled vasodilators worsens the PAWP without hemodynamic benefit.
authors: Pulmonary, Critical Care and Sleep Division, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts, USA.
authors: Ioana R
authors: IR
authors: Preston
authors: Kristen D
authors: KD
authors: Sagliani
authors: Kari E
authors: KE
authors: Roberts
authors: Archan M
authors: AM
authors: Shah
authors: Shilpa A
authors: SA
authors: Desouza
authors: William
authors: W
authors: Howard
authors: John
authors: J
authors: Brennan
authors: Nicholas S
authors: NS
authors: Hill
keywords: heart failure with preserved ejection fraction; inhaled epoprostenol; inhaled nitric oxide; pulmonary arterial hypertension
references: Respir Med. 2005 Dec;99(12):1501-10
references: 15890512
references: Eur Respir J. 1998 Aug;12(2):265-70
references: 9727772
references: Pulm Circ. 2011 Apr;1(2):250-258
references: 22020367
references: Circ J. 2005 Mar;69(3):335-8
references: 15731541
references: Ann Intern Med. 1996 May 1;124(9):820-4
references: 8610951
references: Eur Heart J. 1997 Sep;18(9):1499-504
references: 9458458
references: Chest. 1998 Sep;114(3):780-6
references: 9743166
references: Eur Respir J. 2009 Dec;34(6):1219-63
references: 19749199
references: Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):384-9
references: 7842196
references: Chest. 2010 Feb;137(2):376-87
references: 19837821
references: Circulation. 2005 Jun 14;111(23):3105-11
references: 15939821
references: J Am Coll Cardiol. 2009 Mar 31;53(13):1119-26
references: 19324256
references: J Am Coll Cardiol. 1994 Oct;24(4):982-8
references: 7930234
references: Chest. 2002 Feb;121(2):656-9
references: 11834688
references: N Engl J Med. 1992 Jul 9;327(2):76-81
references: 1603139